Clinical Trial Detail

NCT ID NCT03474107
Title A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

transitional cell carcinoma

Therapies

Enfortumab vedotin-ejfv

Docetaxel + Paclitaxel + Vinflunine

Age Groups: senior adult

No variant requirements are available.